Table 1.
Baseline characteristics.
| N = 32 1 | ||
|---|---|---|
| Gender | ||
| F | 14 (44%) | |
| M | 18 (56%) | |
| Age (years) | 8.5 (5.4, 10.7) | |
| Age, categorical (years) | ||
| ≤2 | 4 (12%) | |
| >2 | 28 (88%) | |
| Weight (kg) | 24 (17, 42) | |
| Baseline disease | ||
| Oncohematological | 22 (69%) | |
| Solid Organ Transplantation | 4 (12%) | |
| Other | 6 (19%) | |
| COVID-19 vaccination | ||
| No | 32 (100%) | |
| Steroid therapy | 13 (41%) | |
| Polytherapy | 19 (59.3%) | |
| COVID-19 symptoms | ||
| Asymptomatic | 11 (34%) | |
| Mild symptoms | 21 (66%) | |
| Mechanical ventilation | 0 (0%) | |
| Non-invasive ventilation | 1 (3%) | |
| Oxygen requirement | 3 (9%) | |
| Type of drug | ||
| Antiviral | 12 (38%) | |
| MAbs | 20 (62%) | |
| COVID-19 drug | ||
| Bamlanivimab–Etesevimab | 1 (3.1%) | |
| Molnupiravir | 2 (6.2%) | |
| Nirmatrelvir – Ritonavir | 3 (9.4%) | |
| Remdesivir | 7 (22%) | |
| Sotrovimab | 19 (59%) | |
| Off-label prescription | 27 (84%) | |
| Serum creatinine (μmol/L) | 36 (26, 56) | |
| AST (U/L) | 48 (30, 69) | |
| ALT (U/L) | 42 (26, 78) | |
| Symptoms after 7 days | Antiviral, N = 12 1 | MAbs, N = 20 1 |
| Asymptomatic | 9 (82%) | 18 (94.8%) |
| Still Symptoms | 2 (18%) | 1 (5.2%) |
| Positivity after 7 days | ||
| Negative | 0 (0%) | 1 (5.2%) |
| Positive | 10 (100%) | 16 (94.8%) |
| Symptoms after 28 days | ||
| Asymptomatic | 10 (100%) | 16 (94%) |
| Still symptoms | 0 (0%) | 1 (5.9%) |
| Positivity after 28 days | ||
| Negative | 6 (60%) | 11 (55%) |
| Positive | 4 (40%) | 5 (33%) |
| Severe ADR | ||
| No | 12 (100%) | 20 (100%) |
| Death for other causes | 1 (8.3%) | 2 (10.5%) |
| Lost to follow-up at 7 days | 1 (8.3%) | 0 (0%) |
| Lost to follow-up at 28 days | 0 (0%) | 1 (5%) |
Legend: 1 n (%); Median (IQR); F: female; M: male; MAbs: monoclonal antibodies; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ADR: adverse drug reaction.